The Stoxx Europe 600 index fell 2% to 496.52 points. Novo Nordisk shares plunged 27%, the biggest one-day drop in 22 years, as the results of the Novo Nordisk weight loss drug CagriSema trial fell short of expectations. Novo Nordisk said on Friday that its experimental next-generation obesity drug CagriSema helped overweight patients lose 22.7% of their weight in a late-stage trial, lower than its expected 25%, causing its shares to fall sharply.